Brief: Aprea Sees Early Activity in APR-1051 Wee1 Trial
24/10/2025 13:42
Oct 24 (Reuters) - Aprea Therapeutics Inc APRE.O: APREA THERAPEUTICS PROVIDES CLINICAL UPDATE FROM ACESOT-1051 TRIAL SHOWING EARLY SIGNALS OF ACTIVITY FOR WEE1 KINASE INHIBITOR APR-1051 APREA THERAPEUTICS INC - NO DOSE LIMITING TOXICITIES OR UNEXPECTED SAFETY ISSUES REPORTED APREA THERAPEUTICS INC - DOSE ESCALATION CONTINUES WITH 150 MG COHORT ENROLLMENT Source text: ID:nGNX2ZzVxr Further company coverage: APRE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aprea Therapeutics
See all newsAprea Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Aprea Therapeutics Q2 net loss widens on higher R&D costs
Aprea Therapeutics Inc expected to post a loss of 23 cents a share - Earnings Preview
Brief: Aprea Therapeutics Provides Acesot-1051 Program Update For Wee1 Inhibitor Apr-1051 Accelerating And Expanding Enrollment. Clinical Data Presentation Planned For Q4 2026
Brief: Aprea Therapeutics - Files For Resale Of Up To 5.5 Million Shares By Selling Stockholders - SEC Filing